Welcome to our dedicated page for Canopy Growth news (Ticker: CGC), a resource for investors and traders seeking the latest updates and insights on Canopy Growth stock.
Canopy Growth Corporation (CGC) generates a steady flow of news as a cannabis-focused manufacturer with operations spanning medical and adult-use markets, branded products, and vaporization devices. The Canopy Growth news page on Stock Titan aggregates these disclosures so readers can follow how the company’s strategy, financing, and operations evolve over time.
Company news frequently covers financial performance and capital structure. Canopy Growth issues quarterly results releases that discuss cannabis and Storz & Bickel net revenue, segment performance in Canada and international markets, gross margins, operating loss, adjusted EBITDA, and free cash flow, along with commentary on cost management and balance sheet strength. The company also announces financing transactions, such as term loan agreements, prepayments on senior secured debt, convertible debenture exchanges, and at-the-market equity programs.
Another major category of news involves corporate transactions and governance. Canopy Growth has reported entering into an arrangement agreement to acquire MTL Cannabis Corp., detailing consideration, required approvals, and expected strategic benefits. It also publishes results of its annual general and special meetings, including director elections, auditor appointments, share consolidation authority, and advisory votes on executive compensation, as well as updates on board and executive appointments.
Product and market updates are a recurring theme. The company announces launches such as Claybourne Gassers liquid diamonds All-in-One vapes and Claybourne Frosted Flyers infused pre-roll variety packs in Canada, along with expansions of the Spectrum Therapeutics medical portfolio in Australia through new softgel formats. It also highlights operational moves like dedicating the DOJA facility in Kelowna to medical cultivation for Spectrum Therapeutics patients.
Investors and observers who monitor CGC news can use this page to track developments in Canopy Growth’s Canadian adult-use and medical businesses, its international medical operations in Europe and Australia, its indirect exposure to the U.S. THC market through Canopy USA, and its ongoing efforts to manage debt, liquidity, and governance matters. Bookmark this feed to review new press releases, transaction updates, and regulatory communications as they are published.
On April 14, 2023, Canopy Growth (NASDAQ: CGC, TSX: WEED) announced an Exchange Agreement with Greenstar Canada Investment Limited Partnership, a subsidiary of Constellation Brands, to extinguish approximately C$100 million (around USD$73.9 million) in unsecured notes due 2023. The agreement involves a cash payment for accrued interest and a Promissory Note of C$100 million, due December 31, 2024, with an interest rate of 4.25%. Following this transaction, Canopy Growth plans to create a new class of Exchangeable Shares that will be convertible into common shares. This strategic move aims to preserve cash and reduce annual expenses as Canopy Growth looks to strengthen its financial position.
Canopy Growth Corporation (CGC) announced a US$150 million offering of senior unsecured convertible debentures with an institutional investor. The initial purchase amounts to US$100 million, with an additional US$50 million contingent on specific conditions. These convertible debentures, bearing an interest rate of 5.0% per annum, will convert into common shares at 92.5% of the average price prior to conversion. Canopy aims to utilize the proceeds for working capital and corporate purposes. Notably, the debentures will not be listed on any exchange, and repayment will occur in common shares on the Maturity Date, February 28, 2028.
Canopy Growth Corporation (CGC) announced a transformation of its Canadian operations to an asset-light model, focusing on profitability. The company aims to cut costs by $140-$160 million over the next 12 months by downsizing its production footprint and reducing headcount by approximately 60%, affecting around 800 positions. Q3 FY2023 financial results showed net revenue of $101 million, down 28% year-over-year, and a net loss of $267 million. Despite challenges, management forecasts positive Adjusted EBITDA in FY2024. The company expects pre-tax charges of $425-$525 million due to restructuring, impacting the current quarter and first half of FY2024.
Canopy Growth Corporation (CGC) will ring the Nasdaq opening bell on December 12, 2022, with CEO David Klein leading the ceremony. This event highlights Canopy's status as a Nasdaq-listed company and its ongoing efforts to establish itself as a leading North American cannabis firm. Klein expressed pride in the company's progress and a commitment to harnessing cannabis's potential for improving lives. The ceremony can be viewed live at 9:15 a.m. ET from the Nasdaq MarketSite Tower in New York City.
Canopy Growth Corporation (CGC) reported Q2 FY2023 financial results, showing a 10% revenue decline year-over-year at $117.9 million, attributed to heightened competition and strategic divestitures. However, net revenue increased 7% sequentially from Q1 FY2023. Notably, BioSteel achieved a 299% revenue growth compared to the prior year. The company announced its strategic plan for U.S. market entry through Canopy USA, which is expected to enhance growth opportunities and profitability following its acquisitions of Acreage, Jetty, and Wana.
Canopy Growth Corporation (NASDAQ: CGC) will announce its financial results for the second quarter of fiscal year 2023, ending September 30, 2022, on November 9, 2022, before market opening. Alongside the results, Canopy Growth will hold a live audio webcast with CEO David Klein and CFO Judy Hong at 10:00 AM ET on the same day. Shareholders can submit questions from November 2 to November 8, 2022. This session will provide insights into the company's performance, future strategies, and shareholder engagement.
On October 24, 2022, Canopy Growth and Canopy USA completed a reorganization resulting in Canopy USA acquiring all of Canopy Growth's interests in TerrAscend Corp. This included 38,890,570 Exchangeable Shares and significant equity options and warrants, resulting in a 100% decrease of Canopy Growth's direct interest. Post-reorganization, Canopy Growth no longer owns any securities in TerrAscend, while Canopy USA controls 100% of the Exchangeable Shares and approximately 19.9% of Common Shares. Future plans regarding these securities remain uncertain, depending on market conditions.
Canopy Growth Corporation announced a strategic move to create a new holding company, Canopy USA, designed to fully capture its U.S. cannabis investments, targeting a market projected to exceed $50 billion by 2026. The formation of Canopy USA enables the acquisition of Acreage Holdings and optimizes the company's balance sheet to facilitate growth opportunities. Canopy aims to consolidate its U.S. cannabis assets, enhancing revenue and operational synergies while positioning itself to benefit from future U.S. federal legalization of cannabis.
Summary not available.
Canopy Growth Corporation (CGC) announced the divestiture of its Canadian retail operations to focus on profitability and premium branding. The company reached agreements with OEG Retail Cannabis and 420 Investments Ltd. for the sale of its stores under the Tweed and Tokyo Smoke banners. These moves are expected to streamline operations and enhance operational savings, aligning with the company’s strategic objectives. The transactions are subject to regulatory approvals, and the closing is anticipated to provide significant cost savings in line with prior operational targets.